Design, Preparation, Characterization and Evaluation of Five Cocrystal Hydrates of Fluconazole with Hydroxybenzoic Acids

To modulate the physicochemical properties of fluconazole (FLZ), a multifunctional antifungal drug, the crystal engineering technique was employed. In this paper, five novel cocrystal hydrates of FLZ with a range of phenolic acids from the GRAS list, namely, 2,4-dihydroxybenzoic acid (24DHB), 3,4-dihydroxybenzoic acid (34DHB, form I and form II), 3,5-dihydroxybenzoic acid (35DHB), and 3,4,5-trihydroxybenzoic acid (345THB) were disclosed and reported for the first time. Crystals of these five hydrates were all obtained for single-crystal X-ray diffraction (SCXRD) analysis. Robust (hydroxyl/carboxyl) O-H. . . Narom hydrogen bonds between acids and FLZ triazolyl moiety were observed to be dominant in guiding these crystal forms. The water molecule plays the role of supramolecular "linkage" in the strengthening and stabilization of these hydrates by interacting with FLZ and acids through O-H. . . O hydrogen bonds. In particular, the formation of FLZ-34DHB-H2O (1:1:1) significantly reduces hygroscopicity and hence improves the stability of FLZ, the latter of which is unstable and easily transforms into its monohydrate form. Increased initial dissolution rates were observed in the obtained cocrystal forms, and an enhanced intrinsic dissolution rate was obtained in FLZ-35DHB-H2O (1:1:1) in comparison with commercialized FLZ form II.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:14

Enthalten in:

Pharmaceutics - 14(2022), 11 vom: 17. Nov.

Sprache:

Englisch

Beteiligte Personen:

Yu, Hongmei [VerfasserIn]
Zhang, Baoxi [VerfasserIn]
Liu, Meiju [VerfasserIn]
Xing, Wenhui [VerfasserIn]
Hu, Kun [VerfasserIn]
Yang, Shiying [VerfasserIn]
He, Guorong [VerfasserIn]
Gong, Ningbo [VerfasserIn]
Du, Guanhua [VerfasserIn]
Lu, Yang [VerfasserIn]

Links:

Volltext

Themen:

Cocrystal
Dissolution
Fluconazole
Hydrate
Journal Article
Stability

Anmerkungen:

Date Revised 13.12.2022

published: Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.3390/pharmaceutics14112486

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM349456275